---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-187012"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T03:05:15.133139+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics Q1 net loss $17.6M; cash $222.8M funds ops into 2029; pipeline on track

## Summary
- Net loss of $17.6M for Q1 2026; R&D expense $14.4M, G&A $5.3M.
- Cash, equivalents and securities total $222.8M as of March 31, 2026, providing runway to 2029.
- DT-216P2 Phase 1/2 RESTORE-FA trial dosing continues; frataxin update expected H2 2026.
- DT-168 Phase 2 FECD trial ongoing with data in H2 2026; DT-818 DM1 Phase 1 MAD trial to begin dosing H1 2026.
- David Shapiro, M.D., appointed to board of directors in March 2026.

## SEC filing metadata
- accession: 0001193125-26-187012
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/0001193125-26-187012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/dsgn-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-187012
- JSON: https://secwatch.observer/filing/0001193125-26-187012.json
- Plain text: https://secwatch.observer/filing/0001193125-26-187012.txt

## Key facts
- Earnings Releases
  Design Therapeutics, Inc. reported the three months ended March 31, 2026 results: net income Net loss was $17.6 million for the quarter ended March 31, 2026..
  - Period: the three months ended March 31, 2026
  - Net income: Net loss was $17.6 million for the quarter ended March 31, 2026.
  - Result: reported results
  source text: Net loss was $17.6 million for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/0001193125-26-187012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.